Patiromer not checked
Vifor Pharma, Inc. · Relypsa, Inc. · RLY5016 for Oral Suspension · RLY5016
FollowEvery change as it happens, and a Monday email
Trials
3 active
14 in total · 5 in the EU
Targets
—
None known yet
What this is
- How it works
- Potassium Binder FDA class
- How it’s given
- “Patiromer will be given once daily; In Cohort 3, depending on the dose and the study participant's age, the total daily dose might be split”In the company’s words, NCT05766839 on ClinicalTrials.gov
- Tested for
- Hyperkalemia
- Main trialPhase 2
- “A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 12 years of age with hyperkalaemia.”In the company’s words, NCT05766839 on ClinicalTrials.gov
- Other names
- Veltassa · RLY5016 for Oral Suspension · RLY5016
Other drugs for Hyperkalemia
- WS016Waterstone Pharmaceutical (Wuhan) Co., LTD. · Phase 3
- Sodium Zirconium CyclosilicateAstraZeneca · Marketed (Phase 4 trial)
Coming up1
- 1 Dec 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials14
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 1 Dec 2029 | Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels | |
| Phase 4Completed | Jul 2016 | Patiromer With or Without Food for the Treatment of Hyperkalemia | |
| Phase 3Completed | Jul 2013 | A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) | |
| Phase 3Completed | 2 Sep 2021 | Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND) | |
| Phase 2Terminated | Dec 2008 | An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis | |
| Phase 2Completed | Nov 2009 | Evaluation of Patiromer in Heart Failure Patients | |
| Phase 2Completed | Sep 2010 | Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease | |
| Phase 2Completed | May 2013 | Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN) | |
| Phase 2Completed | 27 Nov 2018 | Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease | |
| Phase 2Terminated | 13 Jan 2021 | Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia | |
| Phase 2Ended | not given | Double-blind, placebo-controlled clinical trial to determine the effect of Patiromer on vascular function and its relationship with mineral metabolism parameters | |
| Phase 3Ended | not given | A Prospective, double-blind, randomized, single centre trial to evaluate the rate of RAAS inhibitor withdrawal or down-titration in non-dialysis patients with CKD stage IIIB to Vrandomized to Patiromer or placebo | |
| Phase 4Authorised | not given | PROMISE: Potassium correction for RAAS Optimization in Chronic Kidney Disease | |
| Phase 3Authorised | not given | Impact of Patiromer treatment on dietary Potassium intake restriction and health-related quality of life and nutrition in patients on Chronic Dialysis Therapy: a Double-Blind, Prospective, Randomized, Placebo-Controlled, Pilot Trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026